prof. dr. E.G.E. (Elisabeth) de Vries


No picture available


  1. 2012
  2. 2011
  3. Mahalingam, D., Oldenhuis, C. N. A. M., Szegezdi, E., Giles, F. J., de Vries, E. G. E., de Jong, S., & Nawrocki, S. T. (2011). Targeting Trail Towards the Clinic. CURRENT DRUG TARGETS, 12(14), 2079-2090.
  4. Vollebergh, M. A., Lips, E. H., Nederlof, P. M., Wessels, L. F. A., Schmidt, M. K., van Beers, E. H., ... Linn, S. C. (2011). An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Annals of Oncology, 22(7), 1561-1570.
  5. Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., ... RAD001 Adv Neuroendocrine Tumors T (2011). Everolimus for Advanced Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 364(6), 514-523.
  6. Duiker, E. W., de Vries, E., Mahalingam, D., Meersma, G. J., Lub-de Hooge, M. N., Cool, R. H., ... de Jong, S. (2011). ENHANCED ANTI-TUMOR EFFICACY OF A DR5-SPECIFIC TRAIL VARIANT OVER RHTRAIL IN A BIOLUMINESCENT OVARIAN CANCER XENOGRAFT MODEL. In D. Wallach, A. Kovalenko, & M. Feldman (Eds.), ADVANCES IN TNF FAMILY RESEARCH (pp. 796-797). (Advances in Experimental Medicine and Biology; Vol. 691). BERLIN: Springer.
  7. 2010
Previous 12 3 4 5 6 7 8 9 ...20 Next

ID: 162081